Limitation of conventional human Ether-a-go-go Related Gene (hERG) assay and QT prolongation testing for accurate prediction of Torsades de Pointes (TdP) by compounds showed us the necessity of a new approach to evaluate global cardiac safety. As one of the advanced applications of an on-chip cellomics system, on-chip cardiomyocyte cell network-based re-entry model assay has the potential to measure the TdP probability as a pre-clinical test for cardiac safety. This system also can estimate the heart pressure, Na, K, and Ca ion channel conditions using a single cell-based optical/electrical measurement system. In this presentation, we present the system setup and then its possible application for drug discovery and toxicology.

